🧬 Cancer Vaccine Dynamics & Neoantigen Simulator Clinical Trial Phase I/II

1. Vaccine Formulation

Clinical Oncology Preset

Neoantigen Clones (mRNA Targets): 12

MHC-I Binding Affinity (Kd nM): 45 nM Lower Kd = Stronger TCR binding & priming

Somatic Mutations (TMB): 142

Anti-PD-1 / PD-L1 Blockade

Antigen-Loss Escape Rate: 1.2%

Treg / Stroma Density: Normal

Dendritic Cell (DC)

mRNA Neoantigen

CD8+ Cytotoxic T-Cell

Tumor Cell

Anti-PD1 Ab

Zone A: Draining Lymph Node (DC Priming)

Zone B: Tumor Microenvironment (Cytolysis)

Tumor Cells

5,000

CD8+ Cytotoxic Clones

140

Antigen Presentation

92.4%

CD8+ Activation Rate

88.6%

Checkpoint Evasion Mit.

86.0%

Lysis Velocity

740 cells/day

Tumor Clearance & T-cell Expansion Curve